Arcutis Biotherapeutics (ARQT) Amortization of Deferred Charges (2019 - 2025)
Arcutis Biotherapeutics (ARQT) posted quarterly Amortization of Deferred Charges of $111000.0 for Q1 2025, up 14.43% year-over-year from $97000.0 in Q1 2024, and up 3.74% quarter-over-quarter from $107000.0 in Q4 2024.
Arcutis Biotherapeutics (ARQT) Amortization of Deferred Charges (2019 - 2025) Analysis & Trends
Arcutis Biotherapeutics' Amortization of Deferred Charges history runs 7 years deep, the most recent figure standing at $111000.0 for Q1 2025.
- In Q1 2025, Amortization of Deferred Charges rose 14.43% year-over-year to $111000.0; the TTM figure through Mar 2025 stood at $422000.0 (up 14.05% YoY), while the FY2024 annual figure was $408000.0, up 13.33% from the prior year.
- Amortization of Deferred Charges for Q1 2025 stood at $111000.0, up from $107000.0 in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $158000.0 in Q2 2021, with the low at $75000.0 in Q4 2021.
- The 5-year median for Amortization of Deferred Charges is $89500.0 (2023), against an average of $94187.5.
- The sharpest annual moves came in 2021 and 2022: Amortization of Deferred Charges jumped 485.19% in 2021, then plunged 50.0% in 2022.
- Arcutis Biotherapeutics' Amortization of Deferred Charges stood at $75000.0 in 2021, then climbed by 9.33% to $82000.0 in 2022, then increased by 14.63% to $94000.0 in 2023, then increased by 13.83% to $107000.0 in 2024, then grew by 3.74% to $111000.0 in 2025.
- Business Quant data shows ARQT's Amortization of Deferred Charges at $111000.0 in Q1 2025, $107000.0 in Q4 2024, and $103000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 111,000.00 |
| Mar 31, 2025 | 111,000.00 |
| Dec 31, 2024 | 107,000.00 |
| Dec 31, 2024 | 107,000.00 |
| Sep 30, 2024 | 103,000.00 |
| Sep 30, 2024 | 103,000.00 |
| Jun 30, 2024 | 101,000.00 |
| Jun 30, 2024 | 101,000.00 |
| Mar 31, 2024 | 97,000.00 |
| Mar 31, 2024 | 97,000.00 |
| Dec 31, 2023 | 94,000.00 |
| Dec 31, 2023 | 94,000.00 |
| Sep 30, 2023 | 91,000.00 |
| Sep 30, 2023 | 91,000.00 |
| Jun 30, 2023 | 88,000.00 |
| Jun 30, 2023 | 88,000.00 |
| Mar 31, 2023 | 87,000.00 |
| Mar 31, 2023 | 87,000.00 |
| Dec 31, 2022 | 82,000.00 |
| Dec 31, 2022 | 82,000.00 |